US006485746B1

(12) **United States Patent**
Campbell et al.

(10) **Patent No.: US 6,485,746 B1**
(45) **Date of Patent: Nov. 26, 2002**

(54) **CONTROLLED-RELEASE SEDATIVE-HYPNOTIC COMPOSITIONS AND METHODS RELATED THERETO**

(75) Inventors: **D. Bruce Campbell**; **W. Jay Thiele**, both of San Diego, CA (US)

(73) Assignee: **Neurocrine Biosciences, Inc.**, San Diego, CA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/649,343**

(22) Filed: **Aug. 28, 2000**

Related U.S. Application Data

(60) Provisional application No. 60/240,930, filed on Aug. 25, 2000.

(51) **Int. Cl.**[7] **A61K 9/14**; A61K 9/22

(52) **U.S. Cl.** **424/468**; 424/489; 514/772.3; 514/774; 514/778; 514/782; 514/783; 514/781; 514/785; 514/923

(58) **Field of Search** 424/457, 461, 424/462, 463, 476, 480, 481, 482, 489, 468, 465, 490, 494, 495, 496, 497

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,382,938	A	5/1983	Kaplan et al.	424/256
4,460,592	A	7/1984	Kaplan et al.	424/256
4,521,422	A	6/1985	Dusza et al.	514/258
4,626,538	A	12/1986	Dusza et al.	514/258
4,654,347	A	3/1987	Dusza et al.	514/258
4,794,185	A	12/1988	Rossey et al.	546/121
4,808,594	A	2/1989	George et al.	514/300
4,847,256	A	7/1989	Tseng et al.	514/258
4,900,836	A	2/1990	Tomcufcik et al.	546/279
4,948,592	A	8/1990	Ayer et al.	424/473
5,538,977	A	7/1996	Dusza et al.	514/258
5,714,607	A	2/1998	Padmanathan	544/281
5,788,987	A	8/1998	Busetti et al.	424/480
5,891,891	A	4/1999	Benincasa	514/300

FOREIGN PATENT DOCUMENTS

EP	1 005 863 A1	6/2000
EP	1 064 937 A1	1/2001
WO	WO 98/13029	4/1998
WO	WO99/57101	11/1999
WO	WO 00/33835	6/2000
WO	WO01/00181	1/2001

OTHER PUBLICATIONS

Foster, "Developments in CNS Drugs II: Drugs of Tomorrow," SMi Conference, London, UK, May 11–12th, 1999.

Primary Examiner—James M. Spear
(74) *Attorney, Agent, or Firm*—Seed Intellectual Property Law Group PLLC

(57) **ABSTRACT**

Controlled-release formulations providing a "pulsed" plasma profile of a sedative-hypnotic compound having a particularly short half-life are provided. The formulation contains a sedative-hypnotic compound or precursor thereof that is metabolized to generate a sedative-hypnotic compound in vivo, wherein the compound has a mean plasma half life ranging from 0.1 to 2 hours; and at least one release retardant such that, following administration of the formulation to a patient, the patient has specified pulsed plasma profile for the sedative-hypnotic compound as disclosed herein. In a preferred embodiment, the sedative-hypnotic compound is NBI-34060.

35 Claims, 9 Drawing Sheets